Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
25 August 2020 | Story Andre Damons | Photo Pierce van Heerden
Prof Felicity Burt is a passionate virologist with more than 25 years of research on medically significant viruses that cycle in nature and are transmitted to humans via mosquitoes, ticks, or animals.

Prof Felicity Burt, an expert in arbovirology in the Division of Virology, has been leading the University of the Free State (UFS) COVID-19 Task Team over the past five months. Prof Burt is a passionate virologist with more than 25 years of research on medically significant viruses that cycle in nature and are transmitted to humans via mosquitoes, ticks, or animals.

As the UFS is celebrating its champion women this Women’s Month, Prof Burt gives us some insight into who she is. 

Please tell us about yourself

I am an arbovirologist from the Division of Virology in the Faculty of Health Sciences, and the National Health Laboratory Service. Who am I? I am a mum, a wife, a daughter, a sister, a sister-in-law, a friend, a scientist, a colleague, a professor.  I am passionate about my work and have spent more than 25 years researching medically significant viruses that cycle in nature and are transmitted to humans via mosquitoes, ticks, or animals. 
My research group investigates the various mechanisms that viruses use to cause disease, and I am particularly interested in how our bodies respond to infection that can help us develop vaccines or therapies. Raising awareness of these viruses, profiling disease associated with different viruses, and developing tools for surveillance programmes all contribute towards understanding pathogens and the public-health implications. I am so grateful for the opportunities my career has provided me, which includes travelling all over the world for conferences and meetings and participating in outbreak responses in Africa.   
   
Is there a woman who inspires you and who you would like to celebrate this Women’s Month, and why?

I am inspired by all women who set goals and work to achieve them. The goals may vary, but they are important and challenging to each individual.  Hence, I would like us to acknowledge and celebrate all women who achieve their goals through hard work, dedication, and of course, plenty of passion. 

What are some of the challenges you’ve faced in your life that have made you a better woman?

I have always been quite a shy person and still find it challenging to stand up in front of an audience. I was born in Zimbabwe and when I finished school, I moved to South Africa to study at the University of the Witwatersrand. Moving on my own to Johannesburg at the age of 18 was definitely a challenge for a quiet, reserved girl from Harare. Compared to home, Johannesburg was a mammoth city; however, I absolutely loved university life, met people who became lifelong friends, and pursued a career in science. I try to learn from my many mistakes and treat others how I would like to be treated, especially with kindness. 

What advice would you give to the 15-year-old you?

Dream on girl, and it doesn’t matter if they don’t all come true; life isn’t going to turn out as expected, but as long as you enjoy the journey. You don’t have to be the best, but you have to do your best – with passion of course. 

What would you say makes you a champion woman [of the UFS]?

To be honest, I wouldn’t call myself a champion, but I am quite proud of what I have established at the UFS. With hard work and passion, contributions from colleagues, support from management, and never forgetting a whole bunch of wonderfully enthusiastic students, we have built an active postgraduate research group, graduated multiple students, published scientific articles in international journals, presented our research at conferences, contributed to community engagement, had fun, and still have plenty more to achieve!  

 

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept